Given trial heterogeneity (doses, agents, durations), individualization, monitoring, lifestyle support, and collaboration with hepatology are key
Minoxidil demands continuous daily use indefinitely, with discontinuation leading to reversal of gains within 3-4 months
Others affect sleep, mood, or cardiovascular markers
Nakaya, Exendin-4, a GLP-1 receptor agonist, directly induces adiponectin expression through protein kinase A pathway and prevents inflammatory adipokine expression
Retatrutide, a GIP, GLP1 and glucagon receptor agonist, for people with type 2 diabetes: A randomised, doubleblind, placebo and activecontrolled, parallelgroup, phase 2 trial conducted in the USA